Gut–hormone triple agonists: clinical safety and metabolic benefits

  • 1.
    • Day JW
    • Ottaway N
    • Patterson JT
    • et al.

    A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

    Nat Chem Biol. 2009; 5: 749-757

  • 2.
    • Finan B
    • Yang B
    • Ottaway N
    • et al.

    A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

    Nat Med. 2015; 21: 27-36

  • 3.
    • Finan B
    • Ma T
    • Ottaway N
    • et al.

    Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

    Sci Transl Med. 2013; 5209ra151

  • 4.
    • Muller TD
    • Finan B
    • Clemmensen C
    • DiMarchi RD
    • Tschop MH

    The new biology and pharmacology of glucagon.

    Physiol Rev. 2017; 97: 721-766

  • 5.
    • Muller TD
    • Bluher M
    • Tschop MH
    • DiMarchi RD

    Anti-obesity drug discovery: advances and challenges.

    Nat Rev Drug Discov. 2022; 21: 201-223

  • 6.
    • Jastreboff AM
    • Aronne LJ
    • Ahmad NN
    • et al.

    Tirzepatide once weekly for the treatment of obesity.

    N Engl J Med. 2022; 387: 205-216

  • 7.
    • Dahl D
    • Onishi Y
    • Norwood P
    • et al.

    Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial.

    JAMA. 2022; 327: 534-545

  • 8.
    • Del Prato S
    • Kahn SE
    • Pavo I
    • et al.

    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

    Lancet. 2021; 398: 1811-1824

  • 9.
    • Frias JP
    • Davies MJ
    • Rosenstock J
    • et al.

    Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.

    N Engl J Med. 2021; 385: 503-515

  • 10.
    • Ludvik B
    • Giorgino F
    • Jodar E
    • et al.

    Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

    Lancet. 2021; 398: 583-598

  • 11.
    • Rosenstock J
    • Wysham C
    • Frias JP
    • et al.

    Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

    Lancet. 2021; 398: 143-155

  • 12.
    • Coskun T
    • Urva S
    • Roell WC
    • et al.

    LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept.

    Cell Metab. 2022; 34: 1234-1247

  • 13.
    • Knerr PJ
    • Mowery SA
    • Douros JD
    • et al.

    Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.

    Mol Metab. 2022; 63101533

  • 14.
    • Barrington P
    • Chien JY
    • Showalter HD
    • et al.

    A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

    Diabetes Obes Metab. 2011; 13: 426-433

  • 15.
    • Urva S
    • Coskun T
    • Loh MT
    • et al.

    LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.

    Lancet. 2022; 400: 1869-1881